London
· Delayed Price · Currency is GBP · Price in GBXRenalytix Statistics
Total Valuation
Renalytix has a market cap or net worth of GBP 25.67 million. The enterprise value is 31.15 million.
| Market Cap | 25.67M |
| Enterprise Value | 31.15M |
Important Dates
The next estimated earnings date is Friday, March 28, 2025.
| Earnings Date | Mar 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Renalytix has 331.21 million shares outstanding. The number of shares has increased by 27.19% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 331.21M |
| Shares Change (YoY) | +27.19% |
| Shares Change (QoQ) | -23.50% |
| Owned by Insiders (%) | 2.59% |
| Owned by Institutions (%) | 47.67% |
| Float | 248.15M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.90 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.49 |
| EV / Sales | 17.75 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -1.71 |
Financial Position
The company has a current ratio of 0.24
| Current Ratio | 0.24 |
| Quick Ratio | 0.15 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.34 |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -123.74% |
| Return on Capital (ROIC) | -501.75% |
| Revenue Per Employee | 17,204 |
| Profits Per Employee | -205,031 |
| Employee Count | 102 |
| Asset Turnover | 0.19 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -65.56% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -65.56% |
| 50-Day Moving Average | 8.15 |
| 200-Day Moving Average | 18.35 |
| Relative Strength Index (RSI) | 32.45 |
| Average Volume (20 Days) | 249,327 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Renalytix had revenue of GBP 1.75 million and -20.91 million in losses. Loss per share was -0.19.
| Revenue | 1.75M |
| Gross Profit | 223,084 |
| Operating Income | -17.97M |
| Pretax Income | -20.91M |
| Net Income | -20.91M |
| EBITDA | -17.83M |
| EBIT | -17.97M |
| Loss Per Share | -0.19 |
Balance Sheet
The company has 678,205 in cash and 6.16 million in debt, giving a net cash position of -5.48 million or -0.02 per share.
| Cash & Cash Equivalents | 678,205 |
| Total Debt | 6.16M |
| Net Cash | -5.48M |
| Net Cash Per Share | -0.02 |
| Equity (Book Value) | -8.45M |
| Book Value Per Share | -0.05 |
| Working Capital | -6.81M |
Cash Flow
In the last 12 months, operating cash flow was -18.24 million and capital expenditures -2,984, giving a free cash flow of -18.24 million.
| Operating Cash Flow | -18.24M |
| Capital Expenditures | -2,984 |
| Free Cash Flow | -18.24M |
| FCF Per Share | -0.06 |
Margins
| Gross Margin | 12.71% |
| Operating Margin | -1,024.15% |
| Pretax Margin | -1,191.50% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -1,039.41% |
Dividends & Yields
Renalytix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -27.19% |
| Shareholder Yield | -27.19% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |